The invention provides an alpha 7 nicotinic acetylcholine receptor agonist, a composition containing the same, and uses of the agonist for the treatment of a subject suffering from a cognitive impairment, a psychotic disorder, or a neurodegenerative disorder, where the subject is selected for treatment on the basis of CHRNA5 or CHRNA3 genotype.
BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT